Silence Therapeutics (SLN) to Release Quarterly Earnings on Thursday

Silence Therapeutics (NASDAQ:SLN) is expected to be issuing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Silence Therapeutics to announce earnings of ($0.1387) per share and revenue of $1.1680 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 2:00 AM ET.

Silence Therapeutics (NASDAQ:SLN) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.14). The business had revenue of $0.42 million during the quarter, compared to analysts’ expectations of $1.25 million. Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 105.34%. On average, analysts expect Silence Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Silence Therapeutics Stock Up 1.8%

NASDAQ:SLN opened at $10.68 on Tuesday. Silence Therapeutics has a 52 week low of $4.19 and a 52 week high of $12.19. The company has a fifty day simple moving average of $8.94 and a two-hundred day simple moving average of $7.01. The company has a market cap of $504.52 million, a price-to-earnings ratio of -6.72 and a beta of 1.39.

Analyst Upgrades and Downgrades

SLN has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a report on Wednesday, June 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Silence Therapeutics in a report on Friday, July 17th. Finally, Cantor Fitzgerald started coverage on Silence Therapeutics in a research report on Wednesday, June 24th. They issued an “overweight” rating on the stock. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Silence Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $55.00.

Institutional Investors Weigh In On Silence Therapeutics

Several institutional investors have recently modified their holdings of the company. XTX Topco Ltd purchased a new position in Silence Therapeutics in the fourth quarter valued at $71,000. Citadel Advisors LLC purchased a new stake in Silence Therapeutics during the 3rd quarter worth about $112,000. Massar Capital Management LP acquired a new position in shares of Silence Therapeutics during the 2nd quarter worth about $115,000. ADAR1 Capital Management LLC increased its holdings in shares of Silence Therapeutics by 26.8% in the 4th quarter. ADAR1 Capital Management LLC now owns 23,643 shares of the company’s stock valued at $144,000 after acquiring an additional 5,000 shares during the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Silence Therapeutics in the 4th quarter valued at about $177,000. 98.73% of the stock is owned by hedge funds and other institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.